We have recently shown that selective targeting of TNFR2 with the TNFR2 agonist NewStar2 improves AD neuropathology by drastically decreasing Aβ plaque load and enhancing cognition in the J20 AD mouse model [16, 17]. This evidence concerns the gene TNFRSF1B and Alzheimer disease.